Does HRT Cause Joint Pain or Relieve It?

Hormone replacement therapy relieves joint pain for most women going through menopause, but the relationship between HRT and joint health is not as straightforward as “estrogen good, no estrogen bad.” The largest randomized trial ever conducted on the topic found that women taking estrogen reported less frequent joint pain than those on placebo, and stopping HRT led to a rebound in stiffness. Yet a meta-analysis of observational data found that current HRT users had a higher risk of being diagnosed with knee osteoarthritis. The answer depends on whether you are asking about how your joints feel or what is happening to the cartilage inside them.

Why Menopause Makes Joints Hurt in the First Place

Joint pain is one of the most common and least discussed symptoms of the menopausal transition. A systematic review and meta-analysis covering over 93,000 women found that roughly four in ten premenopausal women reported muscle or joint pain, compared with about six in ten perimenopausal and postmenopausal women. The shift from premenopause to perimenopause represented about a 35 percent increase in risk, and the shift to postmenopause about a 40 percent increase.¹ A separate meta-analysis estimated the overall prevalence of musculoskeletal pain among perimenopausal women at about 71 percent, and found that the odds of moderate-to-severe pain increased in a stepwise fashion from premenopause through perimenopause to postmenopause.²

A longitudinal cohort study tracking Chinese women through the menopausal transition confirmed that both the prevalence and severity of muscle and joint pain climbed as menopausal stages progressed, with the late menopausal transition appearing to be a particularly important trigger point for the onset of new symptoms.³ The timing strongly implicates falling estrogen levels, because joint tissues are no longer considered unresponsive to estrogen. Researchers now recognize that estrogen influences the activity of joint tissues through multiple molecular pathways.⁴

What the Largest Trials Show About Pain Relief

The most authoritative evidence on HRT and joint symptoms comes from the Women’s Health Initiative, which randomized thousands of postmenopausal women to either estrogen-based therapy or placebo. In the estrogen-alone arm, women taking conjugated equine estrogens had significantly less frequent joint pain after one year compared with those on placebo, with lower overall pain scores as well.⁵ An overview of the WHI hormone therapy trials also found that women in the combined estrogen-plus-progestin arm were less likely to report joint pain than those on placebo, though the estrogen-alone group in that same overview did not show the same benefit.⁶

The effect sizes here were real but modest. The WHI was not studying women who came in specifically complaining of joint pain; it was tracking a broad population of postmenopausal women and asking about symptoms along the way. That the difference was statistically significant across such a large group, even though the absolute gap in pain scores was small, suggests a genuine biological effect rather than chance. But if you are expecting HRT to make chronic joint pain vanish, the trial data suggests something more like turning the dial down a notch than flipping a switch.

For more localized forms of arthritis, the evidence is thinner. A pilot randomized trial tested estrogen-containing therapy against placebo in women with hand osteoarthritis. Both groups saw decreases in hand pain over 24 weeks, but there was no significant difference between the treatment and placebo groups. The researchers noted the study was designed as a feasibility trial and was not powered to detect a treatment effect, so the door remains open rather than shut.⁷

The Paradox of Symptom Relief and Structural Disease

Here is where the story gets genuinely puzzling. While HRT appears to reduce the experience of joint pain, some evidence points in the opposite direction when it comes to structural joint disease. A meta-analysis looking at HRT and knee osteoarthritis found that HRT use was linked to about a 24 percent higher risk of knee osteoarthritis and a 30 percent higher risk of needing a knee joint replacement. The elevated risk was concentrated among current users of HRT; for past users, the increase was not statistically significant.⁸ A cross-sectional study of middle-aged and older Chinese women found a similar pattern, with HRT use positively associated with both knee pain and clinical knee osteoarthritis.⁹

How can the same therapy reduce pain symptoms in some data and be associated with more structural disease in others? One likely explanation is confounding. Women who go to a doctor for HRT tend to be women with more bothersome menopausal symptoms, including joint pain. In observational studies (unlike the WHI’s randomized design), it is difficult to separate whether HRT caused the knee osteoarthritis or whether women with worse joint problems were simply more likely to seek treatment. A recent systematic review and meta-analysis noted that HRT showed “inconsistent but directionally protective effects” on cartilage, which is academic shorthand for a muddy picture.¹⁰

In other words, the strongest evidence (from randomized trials) says HRT reduces the subjective experience of joint pain. The weaker evidence (from observational studies) raises a flag about structural disease but cannot rule out the possibility that women with worse joints were choosing HRT in the first place.

How Estrogen Affects Joint Tissues

The biological story offers some clarity. Estrogen receptors are present in cartilage cells, and losing estrogen signaling has measurable effects on the structural proteins that hold joints together. Animal studies have shown that knocking out estrogen receptor pathways leads to reduced production of key collagen types and degraded bone integrity beneath the cartilage surface.¹¹

On the inflammatory side, estrogen acts as a brake on several signaling molecules that drive joint inflammation and pain. In women with rheumatoid arthritis, two years of HRT increased levels of a bone-building growth factor while decreasing a receptor that amplifies the activity of a key inflammatory molecule, IL-6. The drop in that receptor also correlated with improved bone mineral density in the spine.¹² Separately, animal research has shown that estradiol decreased levels of pro-inflammatory molecules like TNF-alpha and IL-1-beta in the spinal cord, suggesting estrogen dials down pain-related inflammation in the central nervous system, not just locally in the joints.¹³

This dual action, reducing inflammatory signaling both in the joint and in the central pain-processing pathways, helps explain why women often report less pain when estrogen levels are maintained, even if the structural health of their cartilage is not dramatically transformed.

What Happens When You Stop HRT

One of the more telling pieces of evidence comes from looking at what happens after women discontinue therapy. When WHI participants stopped taking combined estrogen-plus-progestin, former users reported more pain and stiffness than women who had been on placebo the whole time. The researchers interpreted this as evidence of either a genuine beneficial effect of the hormones on musculoskeletal symptoms, a rebound response to stopping therapy, or both.¹⁴

This matters for anyone considering going on or coming off HRT. If you start therapy and your joint pain improves, stopping abruptly could leave you temporarily worse off than if you had never started, at least for a period. The data does not tell us how long this rebound lasts, but it suggests that tapering off gradually and being prepared for a flare of symptoms is a reasonable approach.

What Aromatase Inhibitors Reveal

Some of the strongest indirect evidence that estrogen protects against joint pain comes from the opposite scenario: what happens when estrogen is suppressed even more aggressively than menopause manages on its own. Aromatase inhibitors, used in breast cancer treatment, block the conversion of other hormones into estrogen, creating near-complete estrogen depletion. Joint pain and stiffness are among the most common reasons women discontinue these drugs.

Researchers have proposed that estrogen depletion per se is the link between aromatase inhibitor use and musculoskeletal side effects, and that the normal loss of estrogen during menopause produces a milder version of the same phenomenon. Residual estrogen after natural menopause still acts on bone and on pain-sensing nerve cells, and those effects are lost when aromatase inhibitors suppress estrogen more completely.¹⁵ Mouse models of aromatase inhibitor-induced symptoms have been developed specifically to study the cellular mechanisms behind this toxicity.¹⁶

The aromatase inhibitor experience is a kind of natural experiment. If driving estrogen to nearly zero causes widespread joint pain in most users, it stands to reason that the less dramatic but still significant estrogen decline of menopause contributes to joint pain too, and that partially restoring estrogen through HRT would ease it.

Tendons, Ligaments, and the Stiffness Trade-Off

Estrogen’s effects on the musculoskeletal system are not uniformly positive. While estrogen improves muscle mass and strength and increases collagen content in connective tissues, it decreases stiffness in tendons and ligaments. That reduced stiffness can make joints feel looser and, at high estrogen levels, may even decrease power output and increase the risk of ligament injuries.¹⁷ Lab studies have confirmed that estrogen directly regulates the synthesis of the collagen types that make up ligament structure.¹⁸

For the typical woman taking HRT at standard menopausal doses, this trade-off is unlikely to cause noticeable problems. The doses involved are far lower than the estrogen levels seen in, say, the first trimester of pregnancy (when ligament laxity is well documented). But it is worth knowing that estrogen is not straightforwardly “good for joints” in every tissue type. What helps cartilage and dampens inflammation in the synovial lining may, at extreme levels, loosen the ligaments that stabilize the same joint. At standard HRT doses, the balance tips toward benefit for most women.

Individual Variation and Genetic Factors

Not every woman responds to HRT the same way, and genetics plays a role. Research has found that specific variations in estrogen receptor genes are associated with the likelihood of developing joint pain conditions. Certain genotypes of the ESR1 gene were linked to a higher risk of temporomandibular disorders and jaw joint pain, while variations in the ESRRB gene were associated with articular disorders accompanied by chronic joint pain elsewhere in the body.¹⁷ This means two women with the same estrogen levels might experience very different joint outcomes based on how their estrogen receptors are built and how efficiently they respond to the hormone.

This kind of genetic variability likely explains part of the mixed clinical picture. In any large trial, some women experience dramatic pain relief with HRT while others notice little change. The challenge is that we cannot yet test for estrogen receptor variants in routine clinical practice and use the results to predict who will benefit most. For now, a trial of therapy with attention to symptom response remains the practical approach.

Exercise, Bone Density, and How They Interact with HRT

Exercise is often recommended alongside HRT for menopausal joint symptoms, but the two interventions do not necessarily multiply each other’s effects. A two-year randomized trial in healthy postmenopausal women found that both estrogen-progestin regimens prevented bone mineral density loss in the spine and hip, and also increased the strength of back extensor muscles. Exercise had a positive effect on bone density in the placebo group, but there was no synergistic effect when exercise and estrogen were combined.¹⁹

A separate randomized trial examined whether HRT or exercise affected lumbar spine mobility and low back symptoms. Lumbar mobility decreased in all groups over two years, but the decline was less pronounced in the HRT groups. When the hormone groups were pooled, the difference reached statistical significance. The exercise program, however, did not independently influence spine mobility. Neither HRT nor exercise had a clear preventive or aggravating effect on back symptoms specifically.²⁰

The practical takeaway: exercise is valuable for bone density, cardiovascular health, and general well-being during menopause, but it is not a substitute for HRT when it comes to the specific mechanisms through which estrogen acts on joints and pain pathways. Similarly, HRT on its own will not keep you as strong or as flexible as staying physically active will. The two address partly overlapping but partly different aspects of musculoskeletal health.

When HRT Might Not Be the Right Call for Joint Pain

HRT is not appropriate for everyone, and joint pain alone is not always a sufficient reason to start it. Women with a history of certain cancers, blood clots, or cardiovascular events have well-established reasons to avoid systemic estrogen therapy, and those risks do not change just because their knees hurt. For women whose primary complaint is localized joint pain, particularly hand or knee osteoarthritis that has already progressed structurally, the trial data on HRT’s benefits for those specific conditions is thin at best.

There are also women who start HRT and notice new or worsening joint symptoms. While this is less common than pain relief, it does happen. The reasons are not entirely clear but could involve fluid retention, shifts in weight distribution, or individual differences in how estrogen interacts with already-damaged joint tissues. If joint pain starts or worsens within the first few months of HRT, it is worth discussing with a prescriber rather than assuming the therapy is not working. Dose adjustments, switching formulations, or giving the body more time to adjust can sometimes resolve the issue.

For women who cannot take systemic HRT, the evidence on joint-specific alternatives is limited. Some clinicians use topical estrogen patches in the hope of delivering localized benefit, though there is no strong trial evidence that transdermal estrogen targets joints any differently than oral forms. Anti-inflammatory approaches, physical therapy, and weight management remain the mainstays for menopausal joint pain in women who are not candidates for hormone therapy.